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Background/introduction
In managing women with large uterine fibroids, GnRH
agonists can be used to reduce fibroid volume and
decrease vascularity to enhance treatment outcomes
with MRgFUS. GnRH agonists have been shown to
reduce fibroid volume by as much as 30-40%. The pur-
pose of this study was to examine the responsiveness of
fibroids to pre-treatment with a GnRH agonist in rela-
tion to their appearance on T2 weighted images and
MRgFUS treatment outcomes.
Methods
Fifteen women (ages 34-52) with symptomatic uterine
fibroids were pre-treated with a GnRH agonist prior to
undergoing MRgFUS treatment using the ExAblate
device. 7 patients received treatment for 3 months, 4
received treatment for 4 months, 2 received treatment
for 6 months and 2 received treatment for an unknown
time before the MRgFUS procedure. Other than the 2
patients with unknown GnRH agonist therapy times, all
patients obtained their last GnRH agonist injection 3-4
weeks before MRgFUS treatment. These women were
selected to receive a GnRH agonist if they possessed
fibroids in excess of 10 cm or had a fibroid volume
greater than 300 cc. Fibroids were classified by their
intensity on T2 weighted images relative to normal
myometrium (hypointense, isointense, or hyperintense
as well as tissue homogeneity or heterogeneity). A total
of 22 fibroids were treated with MRgFUS: 17 hypoin-
tense, 3 heterogeneously hypointense, 1 heterogeneously
hyperintense and 1 isointense fibroid. Data regarding
fibroid volume reduction following GnRH administra-
tion, Joules of energy delivered per cc of fibroid tissue
ablated and the final non-perfused volume (NPV) were
investigated.
Results and conclusions
The average reduction in size of fibroids following
GnRH treatment based on T2 appearance was: hypoin-
tense (22%), isointense (44%) heterogeneously hypoin-
tense (33%) and heterogeneously hyperintense (40%).
The average Joules of energy delivered per sonication
was greater for isointense (4550 J) and heterogeneously
hyperintense (4200 J) fibroids than for heterogeneously
hypointense (3227 J) and hypointense (2654 J) fibroids.
Additionally, the volume of tissue ablation per Joule of
energy applied was significantly larger for the heteroge-
neously hypointense (0.066 cm3) and heterogeneously
hyperintense (0.057 cm3) than for the hypointense
(0.036 cm3) and isointense (0.018 cm3). The NPV per
fibroid was greater for heterogeneously hyperintense
(85%), heterogeneously hypointense (63%) and hypoin-
tense (72%) fibroids than for isointense (32%) fibroids.
Fibroid image characteristics may be used to predict the
effectiveness of GnRH agonist therapy prior to MRgFUS
treatment. While more vascular fibroids require greater
energy to treat, they show a more favorable response to
pre-treatment with a GnRH agonist in terms of fibroid
volume reduction and thermoablative treatment effec-
tiveness than hypointense fibroids.
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Figure 1 Sagittal T2-weighted image depicting a 471 cc heterogeneously hyperintense fibroid.
Figure 2 Sagittal T2-weighted image following 3 months of GnRH agonist therapy, showing a 281 cc fibroid representing a 40% reduction in
volume.
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Figure 3 Sagittal post-contrast T1-weighted image following MRgFUS treatment demonstrates a non-perfused volume of 85%.
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